Clinical Trials
58 trialsNEXUS-01
Eli Lilly and Company
FORAGER-2
Eli Lilly and Company
TroFuse-031
Merck Sharp & Dohme LLC
FORAGER-1
Eli Lilly and Company
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
ADVANCED-2
Protara Therapeutics
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Astellas Pharma Inc
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Daiichi Sankyo
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Bristol-Myers Squibb
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen Inc.
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
EV-309
Astellas Pharma Inc
panSOHO
Bayer
DP-04
AstraZeneca
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
enGene, Inc.
MK-3475-04D
Merck Sharp & Dohme LLC
Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
Early is Good Inc.
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
AstraZeneca
MK-3120-003
Merck Sharp & Dohme LLC
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Seagen Inc.
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Pfizer
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Pfizer
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Aura Biosciences
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
EvolveImmune United, Inc
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
CG Oncology, Inc.
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
Bladder EpiCheck Product Development Study
Nucleix Ltd.
INTerpath-011
Merck Sharp & Dohme LLC
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
ENAiBLE
Photocure
DUET-UC-NK
Beijing Biotech
EVER
Verity Pharmaceuticals Inc.
ORI-EGI-03
Origin Sciences
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
RIVERS
AstraZeneca
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Tasca Therapeutics
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
Pilatus Biosciences Inc
GUARDIAN-101
Clasp Therapeutics, Inc.
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
CAMPERR
Adela, Inc
ELEPHAS-05
Elephas
VARTUTRACE
Var2 Pharmaceuticals
ON-5001
OncoNano Medicine, Inc.
BLCCR
Photocure
CREDIBLE
Pacific Edge Limited
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
ORACLE
Guardant Health, Inc.
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Daiichi Sankyo